The 340B Drug Pricing Program was created in 1992 to increase access to hospital outpatient medications for low‐income and uninsured patients by allowing covered entities that serve these patients to ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount program with a lawsuit that challenges the definition of what it means to be a ...

Forbes contributors publish independent expert analyses and insights. I am a cable news contributor and professor of journalism. This voice experience is generated by AI. Learn more. This voice ...

A federal court has struck down a 12-year-old Health Resources and Services Administration policy that restricted how certain 340B hospitals could make initial drug purchases, finding that the agency ...

A federal judge handed down a decision this week in a lawsuit involving the 340B prescription drug discount program as hospitals, physicians, and drug manufacturers continue to battle over how the ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...

On March 17, 2026, the Ninth Circuit issued a unanimous decision in United States ex rel. Adventist Health Sys. of W. v. AbbVie Inc. allowing a large health system to pursue a False Claims Act (FCA) ...

A federal judge handed down a decision this week in a lawsuit involving the 340B prescription drug discount program as hospitals, physicians, and drug manufacturers continue to battle over how the ...

The federal 340B program was created to help low-income patients get access to affordable medicine. But government programs usually explode beyond their original purpose. The same has happened here, ...

Federal complaints by University of Michigan, University of Kansas Hospital Authority, and Mount Sinai entities seek recovery of approximately $250 million in alleged 340B savings diversion from ...